PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 10 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Alkaloid extracts inhibit growth [PMID:28228097]
Exhibits antifungal activity [PMID:27251466, PMID:26573005]
Isolated compounds (CZ 453 and CZ 455) showed antiproliferative/cytotoxic effects, both alone and in combination with doxorubicin and/or chlorambucil [PMID:33623782]
Extracts and pooled surface fractions show antibacterial activity [PMID:37520845, PMID:39220823]
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 28228097 (2017) — Alkaloid extracts from Combretum zeyheri inhibit the growth of Mycobacterium smegmatis. · BMC complementary and alternative medicine
- 2.PMID: 27251466 (2016) — In vitro toxicity determination of antifungal constituents from Combretum zeyheri. · BMC complementary and alternative medicine
- 3.PMID: 33623782 (2021) — The Effects of Combining Cancer Drugs with Compounds Isolated from Combretum zeyheri Sond. and Combretum platypetalum Welw. ex M.A. Lawson (Combretaceae) on the Viability of Jurkat T Cells and HL-60 Cells. · BioMed research international
- 4.PMID: 26573005 (2015) — Isolation and characterization of an antifungal compound 5-hydroxy-7,4'-dimethoxyflavone from Combretum zeyheri. · BMC complementary and alternative medicine
- 5.PMID: 27457758